News
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
Heidelberg Pharma to present first efficacy data on HDP-101 and data from proprietary ADC technology platform at AACR Meeting 2024. Details of ATAC and ADC-based cancer therapies -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
Heidelberg Pharma announces royalty financing agreement with HealthCare Royalty for up to USD 115 million. Agreement to purchase royalties from Telix Pharmaceuticals for Zircaix(TM) -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
Heidelberg Pharma announces royalty financing agreement with HealthCare Royalty for up to USD 115 million. Agreement involves royalties from worldwide sales of Telix Pharmaceuticals' ZircaixTM -
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023